Genetic Testing For Color Vision Makes Commercial Debut for Military Applications
By Dan Buckland,
medGadget
| 06. 12. 2012
Possibly heralding a new era in the use of genetic testing for hiring decisions,
Genevolve (Albuquerque, NM) announced at the recent Aerospace Medicine Association conference in Atlanta, GA a new “military grade” test for inherited color blindness. A few years ago we
posted on research done at the Neitz lab at the University of Washington that used gene therapy to cure color blindness in monkeys. Aspects of that research were used to produce the technology Genevolve uses for its test, called Eyedox. Eyedox uses a buccal swab that is sent to the company, which analyzes the sample for color genes (likely the ones detailed in this review
paper by Neitz) and returns the type of deficiency and severity on a scale of 1-100, 100 being normal.
A press release from the company details what they envision the test could be used for:
“This prevents a qualified applicant from being denied entry into a field they can adequately perform and eliminates cheating or administrator bias that may allow some severely colorblinds to slip through the system,” says [President of Genevolve]...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...